Sensus Healthcare, Inc. · NASDAQ:SRTS
Sensus Healthcare — Q1 2026 Earnings Presentation
23 slides from Sensus Healthcare's earnings presentation, May 7, 2026
Slide 1: 1 in 5 Americans will develop skin cancer in their lifetime
1 in 5 Americans will develop skin cancer in their lifetime – The American Academy of Dermatology
Slide 2: Investor Overview
INVESTOR OVERVIEW NASDAQ: SRTS January 2026
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,”
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS ● Large U.S. market for Superficial Radiation Therapy (SRT) with OUS and pipeline opportunities ● SRT systems continue to deliver 6-9 month ROI for practitioners ● proposed Medicare reimbursement changes (effective 2026) could further improve ROI and adoption ● Launched and sca
Slide 5: Understanding CMS Codes
Understanding CMS Codes Why They Matter for Practices and Patients Precision in coding supports both operational efficiency and clinical excellence CMS Codes: The Foundation of Reimbursement, Access, and Care Delivery • CMS codes define how care is documented, reimbursed, and delivered across 1 in 5
Slide 6: Dedicated SRT CMS Codes
Dedicated SRT CMS Codes A Structural Shift for Adoption Dedicated 2025 CMS Codes for SRT: Clarity, Confidence and Stability • The introduction of dedicated CMS codes for SRT in 2025 represents a meaningful advancement for providers, patients, and the broader dermatology ecosystem. What dedicated SRT
Slide 7: Core Technology: SRT
CORE TECHNOLOGY: SRT LOW-ENERGY PHOTON RADIOTHERAPY ● 100% of the energy is focused directly on surface of skin using customized proprietary applicators SRT-100+ ● Does not penetrate beyond the surface of the skin ● Covered by IP portfolio SCALABLE PLATFORM (potential future indications) ● Being stu
Slide 8: SRT to Treat Non-Melanoma Skin Cancer
SRT TO TREAT NON-MELANOMA SKIN CANCER
Slide 9: Mohs Surgery
Mohs surgery can last for several hours, multiple visits, long heeling time (6-8 weeks) with the patient sitting in a chair with only a local anesthetic MOHS SURGERY
Slide 10: SRT: Superior Cosmetic Outcomes
SRT: Superior Cosmetic Outcomes
Slide 11: SRT to Prevent the Post-Surgical Recurrence of Keloids
SRT TO PREVENT THE POST-SURGICAL RECURRENCE OF KELOIDS
Slide 12: Keloids
Keloids What are Keloids? A keloid is an area of irregular fibrous tissue formed at the site of a scar or injury* *Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225895/ Journal of Family Practice (May 2013); Keloids: Which treatment is best for your patient? Treatment Challenges ● Surgery and
Slide 13: SRT Keloid Outcomes
SRT Keloid Outcomes Before 12-Months After Before 18-Months After Before After
Slide 14: Clinical Studies
CLINICAL STUDIES Skin Cancer ● Clinical multicenter study in 2019 of 776 lesions, 5-year retrospective study (98.9% cure rate) ● Clinical study of 151 lesions on lower extremities in 2018 (97.35% cure rate & 5-year success rate of 97%) ● Cognetta et al. (2012) retrospective analysis on 1,715 confirm
Slide 15: Slide 15
Slide 16: Unique, image-guided therapy: See & treat
Unique, image-guided therapy: “See & treat” The SRT-100 Vision IG-SRT World’s First SRT Designed to: ● Track disease progression ● Plan treatment ● Guided therapy ● Administer radiation ● Evaluate treatment ● Ultrasound capabilities – Image Guided ● 1M+ ultrasound sessions
Slide 17: Full Array of Proprietary Applicators
Full Array of Proprietary Applicators
Slide 18: TransDermal Infusion
TransDermal Infusion Page 18
Slide 19: TransDermal Infusion
TransDermal Infusion No Needles • No Pain • No Downtime - WIP ● Skin rejuvenation ● Hair restoration ● Hyperpigmentation ● PRP ● Regenerative modalities ● Hyaluronic acid ● Growth factor and peptides ● Vitamin C ● Pre- and post-micro-needling treatments ● Hyperhidrosis (botulinum toxin) ● Anesthetic
Slide 20: Sentinel IT Solution
Sentinel IT Solution Introducing our state-of-the-art cloud platform Features DATA & CLOUD REMOTE 1 2 STORAGE DIAGNOSTICS HIPAA iOS 3 COMPLIANT 4 COMPATIBLE
Slide 21: Management Team
Management Team Joseph C. Sardano, Founder, Chairman & CEO Michael Sardano, President & Chief Commercial Officer Javier Rampolla, CFO ▪ Elsci nt Medical Imaging – VP driving Sales & Mktg, led to jo int acquisition ▪ Sensus Healthcare – State & Federal Regulatory ▪ 20+ years of financial experience b
Slide 22: Summary
SUMMARY Disruptive patented technology adaptable to other skin conditions and other cancers Large, growing, underserved market IG-SRT-100 VISION Worldwide installed base currently at 900+ systems Significant advantage to patients compared to existing treatments – NO SCARRING Improved physician produ
Slide 23: What we do
Clinical Dermatology Sentinel 1 2 What we do 4 3 TransDermal Infusion 4